Expert opinion on interleukin-12/23 and interleukin-23 antagonists as potential therapeutic options for the treatment of inflammatory bowel disease

References

• Ben-Horin S, Chowers Y. Review article: loss of response to anti-TNF treatments in Crohn’s disease. Aliment Pharmacol Ther. 2011;33(9):987–995.
   PubMed Web of Science ®Google Scholar
• Enayati PJ, Papadakis KA. Association of anti-tumor necrosis factor therapy with the development of multiple sclerosis. J Clin Gastroenterol. 2005;39(4):303–306.
   PubMed Web of Science ®Google Scholar
• Ramos-Casals M, Roberto-Perez A, Diaz-Lagares C, et al. Autoimmune diseases induced by biological agents: a double-edged sword?. Autoimmun Rev. 2010;9(3):188–193.
   PubMed Web of Science ®Google Scholar
• Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 2001;57(10):1885–1888.
   PubMed Web of Science ®Google Scholar
• Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn’s disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7(8):874–881.
   PubMed Web of Science ®Google Scholar
• Targownik LE, Bernstein CN. Infectious and malignant complications of TNF inhibitor therapy in IBD. Am J Gastroenterol. 2013;108(12):1835–1842. quiz 1843.
   PubMed Web of Science ®Google Scholar
• Pan WJ, Hsu H, Rees WA, et al. Pharmacology of AMG 181, a human anti-alpha4 beta7 antibody that specifically alters trafficking of gut-homing T cells. Br J Pharmacol. 2013;169(1):51–68.
   PubMed Web of Science ®Google Scholar
• Benson JM, Perritt D, Bj S, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3(6):535–545.
   PubMed Web of Science ®Google Scholar
• Zaghi D, Krueger GG, Duffin KC. Ustekinumab: a review in the treatment of plaque psoriasis and psoriatic arthritis. J Drugs Dermatol. 2012;11(2):160–167.
   PubMed Web of Science ®Google Scholar
• Leonard JP, Waldburger KE, Goldman SJ. Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12. J Exp Med. 1995;181(1):381–386.
   PubMed Web of Science ®Google Scholar
• Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn’s disease. N Engl J Med. 2004;351(20):2069–2079.
   PubMed Web of Science ®Google Scholar
• Kauffman CL, Aria N, Toichi E, et al. A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol. 2004;123(6):1037–1044.
   PubMed Web of Science ®Google Scholar
• Niederreiter L, Adolph TE, Kaser A. Anti-IL-12/23 in Crohn’s disease: bench and bedside. Curr Drug Targets. 2013;14(12):1379–1384.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe crohn’s disease. Gastroenterology. 2008;135(4):1130–1141.
   PubMed Web of Science ®Google Scholar
• Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3(2):133–146.
   PubMed Web of Science ®Google Scholar
• Iwakura Y, Ishigame H. The IL-23/IL-17 axis in inflammation. J Clin Invest. 2006;116(5):1218–1222.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, Gasink C, et al. Ustekinumab as induction and maintenance therapy for crohn’s disease. N Engl J Med. 2016;375(20):1946–1960.
   PubMed Web of Science ®Google Scholar
• Weaver KN, Gregory M, Syal G, et al. Ustekinumab in effective for the treatment of crohn’s disease of the pouch in a multicenter cohort. Inflamm Bowel Dis. 2019 Mar 14;25(4):767-774.
   Web of Science ®Google Scholar
• Battat R, Kopylov U, Bessissow T, et al. Association of ustekinumab trough concentrations with clinical, biochemical, and endoscopic outcomes. J Crohns Colitis. 2016;10:S74.
   Web of Science ®Google Scholar
• Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory crohn’s disease. N Engl J Med. 2012;367(16):1519–1528.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, Gasink C, Chan D, et al. Efficacy of ustekinumab for inducing endoscopic healing in patients with crohn’s disease. Gastroenterology. 2018;155(4):1045–1058.
   PubMed Web of Science ®Google Scholar
• Singh S, Fumery M, Sandborn WJ, et al. Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe crohn’s disease. Aliment Pharmacol Ther. 2018 Aug;48(4):394-409.
   Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R et al. Safety and efficacy of ustekinumab induction therapy in patients with moderate to severe ulcerative colitis: results from the Phase 3 UNIFI study [abstract]. Presented at the American College of Gastroenterology (ACG) Annual Scientific Meeting, Philadelphia, Pennsylvania. 5–10 October 2018.
   Google Scholar
• Ochsenkuhn T, Janelidze S, Tillack C, et al. Ustekinumab as rescue treatment in therapy-refractory or intolerant ulcerative colitis [abstract]. Presented at the 13th Congress of European Crohn’s and Colitis Organisation (ECCO), Vienna 2018.
   Google Scholar
• Lightner AL, McKenna NP, Tse CS, et al. Postoperative outcomes in ustekinumab-treated patients undergoing operations for crohn’s disease. J Crohns Colitis. 2018 Mar 28;12(4):402–407.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Naureckas S, Sharma B, et al. Pregnancy outcomes in women exposed to ustekinumab. Gastroenterology. 2018;154(6):S–588 S 589.
   Web of Science ®Google Scholar
• Nguyen GC, Seow CH, Maxwell C, et al. The toronto consensus statements for the management of inflammatory bowel disease in pregnancy. Gastroenterology. 2016;150(3):734–757e1.
   PubMed Web of Science ®Google Scholar
• Mahadevan U, Martin C, Kane S, et al. Do infant serum levels of biologic agents at birth correlate with risk of adverse events?. Gastroenterology. 2016;150(4):S91–S92.
   Web of Science ®Google Scholar
• Geremia A, Arancibia-Carcamo CV, Fleming MP, et al. IL-23-responsive innate lymphoid cells are increased in inflammatory bowel disease. J Exp Med. 2011;208(6):1127–1133.
   PubMed Web of Science ®Google Scholar
• Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;314(5804):1461–1463.
   PubMed Web of Science ®Google Scholar
• Stobie L, Gurunathan S, Prussin C, et al. The role of antigen and IL-12 in sustaining Th1 memory cells in vivo: IL-12 is required to maintain memory/effector Th1 cells sufficient ot mediate protection to an infectious parasite challenge. Proc Natl Acad Sci U S A. 2000;97(15):8427–8432.
   PubMed Web of Science ®Google Scholar
• Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993;178(4):1223–1230.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Sandborn WJ, D’Haens G, et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe crohn’s disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet. 2017;389(10080):1699–1709.
   PubMed Web of Science ®Google Scholar
• Visvanathan S, Baum P, Salas A, et al. Selective IL-23 inhibition by risankizumab modulates the molecular profile in the colon and ileum of patients with active crohn’s disease: results from a randomised phase II biopsy substudy. J Crohns Colitis. 2018 Nov 9;12(10):1170–1179.
   PubMed Web of Science ®Google Scholar
• Feagan BG, Panes J, Ferrantie M, et al. Risankizumab in patients with moderate to severe crohn’s disease: an open-label extension study. Lancet Gastroenterol Hepatol. 2018 Oct;3(10):671–680.
   PubMed Web of Science ®Google Scholar
• Gordon K, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltlMMa-1 and UltlMMa-2): results from two double-blind, randomized, placebo-controlled and ustekinumab controlled phase 3 trials. Lancet. 2018;392(10148):p650–651.
   PubMed Web of Science ®Google Scholar
• Sands BE, Chen J, Feagan BG, et al. Efficacy and safety of medi2070, an antibody against interleukin 23, in patients with moderate to severe crohn’s disease: a phase 2a study. Gastroenterology. 2017;153(1):77–86 e6.
   PubMed Web of Science ®Google Scholar
• Schmechel S, Konrad A, Diegelmann J, et al. Linking genetic susceptibility to crohn’s disease with Th17 cell function: IL-22 serum levels are increased in crohn’s disease and correlate with disease activity and IL23R genotype status. Inflamm Bowel Dis. 2008;14(2):204–212.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Ferrante M, Bhandari BR, et al. Efficacy and safety of anti–interleukin-23 therapy with mirikizumab (Ly3074828) in patients with moderate-to-severe ulcerative colitis in a phase 2 study [DDW abstract 882]. Gastroenterology. 2018;154(suppl1):S1360–S1361.
   Google Scholar
• Deodhar A, Gottlieb AB, Boehncke WH, et al. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study. Lancet. 2018;391(10136):2213–2224.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417.
   PubMed Web of Science ®Google Scholar
• Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418–431.
   PubMed Web of Science ®Google Scholar